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Interventions Using Wearable Physical Activity Trackers Among Adults
With Cardiometabolic Conditions
A Systematic Review and Meta-analysis
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Abstract
IMPORTANCE Wearable physical activity (PA) trackers, such as accelerometers, fitness trackers, and
pedometers, are accessible technologies that may encourage increased PA levels in line with current
recommendations. However, whether their use is associated with improvements in PA levels in
participants who experience 1 or more cardiometabolic conditions, such as diabetes, prediabetes,
obesity, and cardiovascular disease, is unknown.
OBJECTIVE To assess the association of interventions using wearable PA trackers (accelerometers,
fitness trackers, and pedometers) with PA levels and other health outcomes in adults with
cardiometabolic conditions.
DATA SOURCES For this systematic review and meta-analysis, searches of MEDLINE, Embase,
Cochrane Central Register of Controlled Trials, and PsycINFO were performed from January 1, 2000,
until December 31, 2020, with no language restriction. A combination of Medical Subject Heading
terms and text words of diabetes, obesity, cardiovascular disease, pedometers, accelerometers, and
Fitbits were used.
STUDY SELECTION Randomized clinical trials or cluster randomized clinical trials that evaluated the
use of wearable PA trackers, such as pedometers, accelerometers, or fitness trackers, were included.
Trials were excluded if they assessed the trackers only as measuring tools of PA before and after
another intervention, they required participants to be hospitalized, assessors were not blinded to the
trackers, or they used a tracker to measure the effect of a pharmacological treatment on PA among
individuals.
DATA EXTRACTION AND SYNTHESIS The study followed the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. A random-effects model was
used for the meta-analysis.
MAIN OUTCOMES AND MEASURES The primary outcome was mean difference in PA levels. When
the scale was different across studies, standardized mean differences were calculated.
Heterogeneity was quantified using the I2 statistic and explored using mixed-effects metaregression.
RESULTS A total of 38 randomized clinical trials with 4203 participants were eligible in the
systematic review; 29 trials evaluated pedometers, and 9 evaluated accelerometers or fitness
trackers. Four studies did not provide amenable outcome data, leaving 34 trials (3793 participants)
for the meta-analysis. Intervention vs comparator analysis showed a significant association of
wearable tracker use with increased PA levels overall (standardized mean difference, 0.72; 95% CI,
0.46-0.97; I2 = 88%; 95% CI, 84.3%-90.8%; P < .001) in studies with short to medium follow-up for
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Key Points
Question Are interventions using
wearable physical activity (PA) trackers,
including accelerometers, fitness
trackers, and/or pedometers, associated
with improved PA levels among people
with cardiometabolic conditions?
Findings In this systematic review and
meta-analysis of 38 randomized clinical
trials with 4203 participants,
interventions with wearable PA trackers
were associated with significantly
increased PA levels during
approximately 15-weeks follow-up;
interventions (particularly pedometers)
with additional components, such as
consultations with health care
professionals, were associated with
increased PA levels.
Meaning The findings suggest that use
of wearable PA trackers (especially
pedometers) is associated with
increased PA levels among people with
cardiometabolic conditions when
combined with additional intervention
components, such as face-to-face
consultations, but these PA level
improvements may remain below the
targets set by clinical recommendations.
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Abstract (continued)
median of 15 (range, 12-52) weeks. Multivariable metaregression showed an association between
increased PA levels and interventions that involved face-to-face consultations with facilitators (23
studies; β = −0.04; 95% CI, −0.11 to −0.01), included men (23 studies; β = 0.48; 95% CI, 0.01-0.96),
and assessed pedometer-based interventions (26 studies; β = 0.20; 95% CI, 0.02-0.32).
CONCLUSIONS AND RELEVANCE In this systematic review and meta-analysis, interventions that
combined wearable activity trackers with health professional consultations were associated with
significant improvements in PA levels among people with cardiometabolic conditions.
JAMA Network Open. 2021;4(7):e2116382. doi:10.1001/jamanetworkopen.2021.16382
Introduction
A large proportion of the population experiences cardiometabolic conditions, such as type 2
diabetes, prediabetes states (eg, obesity), and cardiovascular disease.1,2 In the UK, 3.3 million people
have been diagnosed with type 2 diabetes, and most of them experience additional cardiometabolic
conditions or risks, including obesity, increased blood pressure, disturbed blood lipid levels, and a
tendency to develop thrombosis and cardiovascular disease.3 The increasing prevalence of
cardiometabolic conditions combined with demographic changes mean that the overall
cardiometabolic costs will account for more than 20% of the entire National Health Service budget
in the next 20 years, with most of these costs being avoidable.4
Despite the health and economic consequences of cardiometabolic conditions, they are mainly
lifestyle related and can be improved by targeting unhealthy lifestyle behaviors. Particularly, a low
physical activity (PA) level is a fundamental modifiable risk behavior for people with cardiometabolic
conditions and is a major opportunity for intervention.5 Premature deaths could potentially be
prevented by addressing low levels of PA more so than any other risk factor,6 such as smoking,
alcohol consumption, or stress-related illnesses. Recognizing the importance of PA, several public
health guidelines recommend reaching and maintaining health-enhancing levels of PA7 and promote
PA interventions in the community and the workplace.8-10 However, promoting PA for people with
cardiometabolic conditions remains a challenge.11
Wearable activity trackers may empower people with cardiometabolic conditions to improve
their PA levels and health behaviors. These devices include simple activity trackers, such as
pedometers (a portable electrical or electromechanical tracker that counts each step a person takes
by detecting the motion of the person along the body’s long axis)12 and accelerometers or fitness
trackers (electromechanical trackers used to measure acceleration forces by the use of algorithms to
accurately detect periods of wear and nonwear time).13 These wearable activity trackers have
recently become popular for motivating people to be more active and monitoring that activity among
people with a range of chronic conditions, including cardiometabolic conditions.14 The devices are
simple, relatively affordable, user-friendly, and potentially motivational.15
A number of previous systematic reviews16-19 suggest that these wearable trackers may be
associated with increased PA levels among people with chronic conditions, including cardiometabolic
conditions. However, there is limited evidence on whether interventions that involve wearable
activity trackers are associated with improved PA levels among people with cardiometabolic
conditions in the short and long terms. Moreover, to our knowledge, factors that may moderate the
effectiveness of these interventions (eg, intervention or patient factors) have not been examined
using robust methods, such as metaregression. These knowledge gaps are major barriers for the
wider use of these monitoring devices in the care of people with cardiometabolic conditions.
Our earlier systematic review20 was retracted based on a complex issue that involved the
intervention definition, which affected the inclusion criteria for 9 of the 36 studies included in the
original systematic review. Thus, in this updated systematic review and meta-analysis, we examined
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whether interventions that use activity trackers (pedometers, accelerometers, or fitness trackers) as
part of the program design were associated with short-term and long-term improvements in PA
levels and health outcomes, including blood glucose levels, blood pressure, cholesterol levels, body
weight, and body mass index (BMI; calculated as weight in kilograms divided by height in meters
squared), among people with cardiometabolic conditions compared with usual care. Metaregression
was also used to examine whether an association with increased PA levels in the intervention group
vs comparator group was moderated by the characteristics of the interventions (type of wearable
tracker, setting daily goals, use of consultations with facilitators, evaluation length, use of a
theoretical framework, and uptake rate) and patients (age, sex, and index condition).
Methods
This systematic review and meta-analysis (CRD42018104448) was conducted and reported in
accordance with the Cochrane Handbook21 and the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) reporting guideline.22 Searches were performed in the
Cochrane Central Register of Controlled Trials (CENTRAL), Embase, MEDLINE and PsycINFO from
January 1, 2000, until December 31, 2020, with no language restriction. January 2000 was used
because an earlier review16 reported that no studies were found before this date. A combination of
Medical Subject Heading terms and text words of diabetes, obesity, cardiovascular disease,
pedometers, accelerometers, and Fitbits were used. The full search strategy in MEDLINE is available
in eTable 1 in the Supplement. Additional studies were obtained from screening the reference lists of
included trials and previous systematic reviews. Experts were contacted in the field to inquire about
unpublished studies. Trial registers (ClinicalTrials.gov, ISCTRN, the World Health Organization
International Clinical Trials Registry Platform, and OpenTrials.net) were also searched to identify any
unpublished or ongoing trials.
Eligibility Criteria
Population
Adults 18 years or older with a diagnosis of type 2 diabetes (or at risk for type 2 diabetes), obesity or
overweight, and cardiovascular disease were eligible for inclusion. For obesity classification, the
World Health Organization definition was used to standardize across studies.23 Studies of people
diagnosed with stroke or who had undergone surgery were excluded.
Intervention
Randomized clinical trials (RCTs) or cluster RCTs that evaluated the use of wearable activity trackers,
such as pedometers, accelerometers, or fitness trackers, were part of the intervention program.
Excluded trials were those that used the wearable trackers only as measuring tools of PA before and
after another intervention (and thus were not part of the interventional program design), those that
required participants to be hospitalized, those in which assessors were not blinded to the wearable
trackers, and those that used a wearable tracker to measure the effect of a pharmacologic treatment
on an individual’s ability to be physically active.
Comparator and Outcome
Participants using wearable activity trackers were compared with a group receiving usual care. The
primary outcome was the association of the use of an activity tracker with PA levels. Secondary
outcomes were body weight or BMI, blood glucose level, blood pressure, and cholesterol levels.
Data Collection and Extraction
Titles and abstracts were assessed by 3 reviewers (A.H., M.P., and C.A.). Data extraction was
conducted by 1 reviewer (A.H.) and checked by a second (C.A.) for consistency. A modified version of
the Cochrane Public Health Group’s data extraction template24 was used after pilot testing on 5
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studies to ensure reliability. The Oxford Implementation Index was used to assess implementation of
the intervention and contextual factors.25 This index was adapted for the purposes of this review.
Assessment of Risk of Bias
Risk of bias for each study was assessed by 2 reviewers (A.H., C.A.) using the original version of the
Cochrane Risk of Bias tool.26 The blinding of participants and personnel was not included in the risk
of bias assessment because many studies did not report this domain since it was impossible to blind
participants while they were using the technology device. If further information was required on any
aspect of study design or outcome, related publications and trial protocols were sought and authors
were contacted. Adjustment for cluster RCTs was performed in accordance with the Cochrane
Handbook (§23.1.4).21
Missing Data
Study authors were contacted by email where there were missing or unclear data (for instance
relating to the primary outcome). Studies for which insufficient primary data were available (eg,
missing data cannot be obtained) were excluded from the meta-analysis but not from the review.
Statistical Analysis
The statistical analysis proceeded in 2 stages. First, Hartung-Knapp-Sidik-Jonkman random-effects
meta-analyses27 were conducted to assess the association of the interventions with the primary and
secondary outcomes compared with controls. The Hartung-Knapp-Sidik-Jonkman method was used
instead of the DerSimonian-Laird random-effects method because it is globally thought to be a more
robust method of choice when study sizes are small and considerable heterogeneity is present.
Because all outcomes were continuous, standardized mean differences (SMDs) were calculated using
Hedges g.28 Standardized mean differences were interpreted according to the Cohen rule of
interpretation in accordance with the Cochrane guidelines (ie, small effect, 0.2; moderate effect, 0.5;
and large effect, 0.8).29,30 When required, data were transformed to SMDs using Comprehensive
Meta-analysis software.31 Physical activity outcomes were objectively classified by intervention
measure (ie, daily step count or moderate to vigorous physical activity [MVPA]). Pooled associations
with 95% CIs are presented, and forest plots with I2 and the test-based 95% CIs32 are used to show
statistical heterogeneity among studies. When a study contributed more than 1 intervention arm to
the analysis, the arms were combined to avoid double counting of the control group. When data were
judged to be insufficient to include in meta-analyses, the results were synthesized narratively.
Second, mixed-effects univariable and multivariable (multilevel) metaregression analyses
examined the association of several study-level covariates with the primary outcome (PA levels). The
multilevel aspect of the regression model allowed for potential clustering by including random
effects for tracker type and study. Ten covariates were selected based on importance and
consultation among the authors. Then the categories for the covariates were coded using consensus
procedures and as informed by the Oxford Implementation Index25: (1) sex classified by dominance
in each study (ie, mostly male or female), (2) age (<50 vs 50 years), (3) index condition (ie, type 2
diabetes, overweight or obesity, or cardiovascular disease), (4) type of tracker, (5) outcome measure
used to assess PA (steps per day or MVPA), (6) consultations with facilitators, (7) intervention length
(4 vs >4 months), (8) goal set for physical activity, (9) theory-based intervention, and (10)
intervention uptake. Low risk of bias based on all 5 domains that were judged to be low risk was
assessed against the high-risk studies with at least 1 high-risk domain in a sensitivity analysis.
Covariates that met our significance criterion (2-sided P < .15) were entered into a multivariable
metaregression model. The P < .15 threshold was conservative to avoid prematurely discounting
potentially important explanatory variables, and adjusted tests were used for controlling type I
error.33 All analyses were performed using the meta and metafor packages in R, version 4.0.3 (R
Foundation for Statistical Computing). For each meta-analysis with 10 studies or more, funnel plots,
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the Begg test, and the Egger test were used to examine publication bias. The trim-and-fill method
was used as a sensitivity analysis to observe possible small study publication bias.
Results
After duplicates were removed, the search retrieved 5670 references. After abstract and title
screening of 2754 references and full-text screening of 147 studies, 38 studies34-82 met our inclusion
criteria (Figure 1). All eligible studies are listed in eTable 2 in the Supplement. No unpublished studies
were identified.
Characteristics of Included Studies
Location, Setting, and Participant Characteristics
Most studies34-39,41-43,45,76,82 were conducted in the US (n = 12) or UK (n = 6). The settings of the
studies varied and included hospitals, primary care practices, medical and community centers, and
universities. The 38 studies34-82 involved 4203 participants (Table 1). All the studies included adults
with a mean age between 35 and 67 years; 16 studies38,42,43,50,51,53,54,65-67,69,71,72,75,78,79 focused on
older adults with a mean age older than 60 years. Two studies34,35 included women only, and the
remainder36-82 involved mixed-sex populations. The target population recruited in the studies was
predominantly those diagnosed with type 2 diabetes (n = 23), but other diagnoses included
cardiovascular diseases (n = 8) and obesity or mixed obesity and overweight (n = 7).
Intervention and Outcome Characteristics
Twenty-nine studies34-39,41,46,48-51,53,55,57,65-78 involved pedometers as part of the intervention
program to encourage PA, whereas 9 studies42,43,45,54,56,79-82 used accelerometers or fitness
trackers as part of the intervention program to encourage PA. In terms of content, interventions
focused mainly on the association with PA levels, prevention of disease, and weight management
(eTable 3 in the Supplement). Seventeen studies36,38-41,48-51,55,64,65,71,74,76-78,82 (42%) used a
theoretical framework that consisted of social cognitive approaches (eg, health belief model, theory
of planned behavior, or transtheoretical model); however, behavior change outcomes were not
reported in the results of 11 studies.36,38,41,46,48,49,51,54,71,72,76,77 Twelve
studies34,36,37,39,42,50,51,54,56,70,73,82 tested simple pedometer, accelerometer, or fitness tracker
interventions. This finding meant, for instance, that after an initial consultation session, patients
were provided with the accelerometer, fitness tracker, or pedometer and a log book to self-monitor
their outcomes using written instructions, but no additional support was provided by facilitators or
health care professionals. A total of 26 studies35,38,41,43,45,46,48,49,53,55,57,64-69,71,72,74-81 (61%) tested
interventions that also involved consultation sessions (ie, patients were supported by facilitators
Figure 1. Flow Diagram of Screening Stages
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citation searching
2754 Records screened at title and
abstract after duplicates removed
2607 Records excluded











147 Full-text articles assessed 
for eligibility
38 Studies included in reviewa
34 Studies included in meta-analysesa
RCT indicates randomized clinical trial.
a No unpublished studies were found.
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Table 1. Participant Characteristics From Eligible Studies
Source
Participants
















38 US 57 (10.8) Intervention: 3 of 18
female (17%); control: 8
of 20 female (40%)
57% White Coronary artery disease No
Andrews et al,46
2011











30 Mexico Intervention: 49 (11);
control: 51 (10)









14 male; control: 8
female, 17 male
NR Type 2 diabetes
diagnosed (age <80 y)
Intervention (6 of
23) and control








199 Poland Intervention: 62 (7);
control: 63 (7)
Intervention: 29 male
(34%); control: 26 male
(33%)








45 UK Intervention: 61.6
(11.3); control: 59.2
(8.9)














Type 2 diabetes and/or
hypertension
No
De Greef et al,64
2010
41 Belgium NR 68% Male NR Type 2 diabetes
diagnosed during 6 mo
No
De Greef et al,71
2011





47 Belgium Overall: 67.4 (9.3) 70.1% Male; 29.9%
female





32 US Intervention: 56.68
(13.62); control: 54.88
(9.79)









11 female; control: 15
male, 15 female














181 US Intervention: 36.62
(5.07); usual care:
35.62 (5.76)
100% Female 100% Black Overweight or obesity











3% Black, 3% Asian,
other 3%; control: 100%
White







65 Canada Intervention: 58 (8);
control: 59 (9)
14 of 65 Female (21.5%) NR Acute coronary syndrome No
Katzmarzyk et al,37
2011












127 UK Intervention 1: 60.9
(9.6); intervention 2:
63.2 (10.6); usual care:
59.2 (10.4)
Intervention 1: 53% male
and 47% female;
intervention 2: 42% male
and 58% female; usual
care: 51% male and 49%
female
NA Type 2 diabetes No
Lewis et al,38
2020
40 US Intervention: 63.2
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who were mainly health care professionals via face-to-face consultations and/or regular
telecommunications during the intervention). The median duration for receiving the intervention
was 17 weeks, but this varied considerably across studies (range, 1 week to 18 months). Physical
Table 1. Participant Characteristics From Eligible Studies (continued)
Source
Participants












and 8 female; control: 6
male and 14 female
Intervention: 80% White;
control: 90% White
Type 2 diabetes Yes
Pekmezi et al,39
2017
76 US Overall: 57 (4.7) 100% Female 100% African American Overweight and obesity No
Piette et al,76
2011
339 US 56 (10.1) 51.5% Female White: 84%; Black: 9%;
other: 7%





287 Canada Group 1: 61 (11.7);
group 2: 61.4 (12.6);
group 3: 62.3 (11.1)
Group 1: 46.8% female;
group 2: 40.6% female;
group 3: 51% female
NR Type 2 diabetes Yes
Silfee et al,41
2016









90.9% White, 9.1% Black









Van Dyck et al,78
2013
92 Belgium Overall: 62 (9) 69% Male NR Type 2 diabetes
diagnosed at age >5 y and













571 UK Overall: 62.6 (8.2) 65.5% Male 86.8% White European Individuals 18-74 y of
age were included if they
scored >90th percentile
on the risk calculator (a
noninvasive risk















and 11 female; control:
49 male and 11 female



















Interval walking: 7 male
and 5 female; continuous
walking: 8 male and 4
female; control: 5 male
and 3 female
NR Type 2 diabetes Yes
Lyons et al,42
2017
40 US 61.48 (5.60) 85% Female 65% White, 13% Black,
15% other
Overweight or obesity Yes
Lystrup et al,43
2020
120 US Intervention: 64 (9);
control: 63 (7)
Intervention: 59.6%





Type 2 diabetes No
Martin et al,82
2015
48 US 58 (8) 54% Male 79% White CVD rehabilitation Yes
Miyamoto et al,56
2017
31 Japan LPA: 61.7 (1.9); N-LPA:
60 (3.1); control: 60.2
(3)
LPA: 9 male and 2
female; N-LPA: 9 male
and 3 female; control: 8
male and 2 female





26 US Intervention: 48.8
(6.1); control: 47 (7.2)
53% Female in each
group
NR Obesity and type 2
diabetes
No
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CVD, cardiovascular disease; LPA, locomotive physical activity; NA, not
applicable; N-LPA, nonlocomotive physical activity; NR, not reported; SES, socioeconomic status.
a Median (interquartile range).
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activity was measured using steps per day in 25 studies34,37,41-43,48,50,51,55,65-78,81,82 (66%) and MVPA
in 9 studies36,38,39,45,46,49,54,56,80 (24%).
Risk of Bias
The quality of the studies was variable (eTable 4 in the Supplement). A total of 22
studies37,39,42,45,46,49-51,54-56,66,68-74,76,78,79,82 (58%) had a low risk of bias for the random sequence
generation, and 20 studies37,41-43,46,49-51,54,60,64,65,68,69,71,72,75,76,78 (53%) had low risk for allocation
concealment. Only 1 study36 was deemed high risk for this criterion. Similarly, blinding of outcome
assessment was moderately reported, with 16 studies49,51,53,55,57,66,68-72,74,78,79,81,82 (42%) reporting
low risk; however, 12 studies34,35,38,41-43,45,46,48,54,73,76 (32%) reported high risk for this domain.
Criteria for incomplete outcome data were mostly satisfied across studies, displaying low risk in 27
studies34,37,38,42,43,46,48-51,53-56,66,69-72,74-80,82 (70%); however, 8 studies35,36,41,57,65,69,73,77 (21%)
reported high risk. For selective reporting, only 3 studies37-39 (8%) exhibited high risk of bias.
Synthesis of Results
Thirty-four of the 38 studies34,36-52,54-56,58-78,80-82 (89%) were included in the meta-analysis,
involving 3793 participants. The exclusion of 4 studies35,53,57,79 was because the studies were not
amenable for inclusion. The results of those studies are reported narratively in the Narrative
Synthesis subsection of the Results section.
PA Levels
Summary estimates from the meta-analyses are presented in Table 2. Across all
studies34,36-52,54-56,58-78,80-82 that involved interventions with wearable activity trackers vs
comparators, there was a significant association between wearable tracker use and increased PA
during an approximately 15-week period (SMD, 0.72; 95% CI, 0.46-0.97; prediction interval, −0.72 to
2.16; I2 = 88%; 95% CI, 84.3%-90.8%; P < .001) (eFigure 1 in the Supplement). Pedometer-based
interventions were significantly associated with increased PA compared with comparators (SMD,
0.68; 95% CI, 0.44-0.93). Accelerometer- and fitness tracker–based interventions were not
associated with increased PA compared with comparators (SMD, 0.92; 95% CI, −0.10 to 1.94). For
pedometer-based interventions, the PA measure translated to 1877.30 steps per day (95% CI,
1139.70-2614.90 steps per day) in the intervention group compared with the usual care group
(eFigure 2 in the Supplement). This value is generally lower than recommendations of governments
and agencies globally,61 with a mean of 3000 steps being achieved daily (National Obesity Forum UK:
3000-6000 steps per day as sedentary; America on the Move: an additional 2000 steps each day
to stop weight gain). Heterogeneity was high for both interventions encompassing pedometer use
(I2 = 89%; 95% CI, 85%-92%) and accelerometer or fitness tracker use (I2 = 86%; 95%
CI, 74%-92%).
The cumulative plot (eFigure 3 in the Supplement) of PA performance based on total session
time engagement provided no evidence that studies with longer periods of engagement in PA
performed better in general. However, 9 studies38,43,44,48,50,69,70,76,81 did not report the length of
the sessions and therefore could not be included.
Moderators of Associations
The results of the univariable and multivariable analyses are given in Table 3. Interventions using
consultations with a health care professional (β = 0.45; 95% CI, 0.001-0.93; P = .04), pedometer-
based interventions (β = 0.29; 95% CI, 0.02-0.38; P = .03), steps per day used as outcome
measurement (β = 0.48; 95% CI, 0.04-0.76; P = .04), and the inclusion of predominately male
participants in studies (β = 0.19; 95% CI, 0.03-0.29; P = .02) were associated with improved PA
levels in the univariable regression analyses. The remaining factors, including index diagnosis of
participants, age of participants, length of the intervention, goal setting, underpinning the
intervention with a theoretical framework, intervention uptake, and risk of bias scores, were not
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associated with PA level and were not eligible for inclusion in the multivariable regression analysis.
The overall multivariable model was statistically significant (χ 23 = 24.18; P = .03), and the I
2 statistic
decreased from 68% to 39%. Consultations with a health care professional (b = −0.04; 95% CI, −0.11
to −0.01; P = .01), pedometer use (b = 0.20; 95% CI, 0.02-0.32; P = .004), and male sex (b = 0.48;
95% CI, 0.01-0.96, P = .046) remained significantly associated with increased PA in the multivariable
model. Thus, interventions that involved regular consultations with health care professionals
(compared with self-monitoring only), male sex, and pedometer-based interventions (compared
with accelerometers and fitness trackers) were the 3 main factors associated with improved
PA levels.
A post hoc subgroup analysis was conducted using the enhanced consultation and monitoring
device variables whereby studies were divided into 4 groups to best visualize the results of the metare-
gression analyses (Figure 2). Pedometer interventions that incorporated consultations with health care
professionals were associated with increased PA (SMD, 0.83; 95% CI, 0.53-1.14) as were unsupervised
pedometer interventions (SMD, 0.28; 95% CI, 0.02-0.53). Accelerometer and/or fitness tracker inter-
ventions with consultations and without consultations were not associated with increased PA.
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34 3793 15 NA NA NA 0.72 (0.46 to 0.97) 88 (84.3 to 90.8) <.001
Accelerometer and
fitness tracker
8 414 12 NA NA NA 0.92 (−0.10 to 1.94) 86 (74.4 to 92.3) <.60b
Pedometer 26 3379 15 1877.30 (1139.70 to
2614.90)
96 (95 to 96.8) <.001 0.68 (0.44 to 0.93) 89 (85.1 to 91.9) NA
Outcome measure
Steps per day 25 2893 15 NA NA NA 0.85 (0.53 to 1.17) 90 (86.5 to 92.6) .008b
MVPA 9 900 12 NA NA NA 0.30 (0.00 to 0.61) 47 (0 to 75.4) NA
Secondary outcome
measures
Glucose level, % 26 2069 24 −0.14 (−0.27 to −0.01) 80 (71.4 to 86) .04 NA NA NA
Accelerometer and
fitness tracker
5 415 26 0.00 (−0.24 to 0.23) 0 (0 to 79.2) .10b NA NA NA
Pedometer 13 1654 26 −0.19 (−0.35 to −0.03) 85 (75.9 to 90.7) NA NA NA NA
Blood pressure,
mm Hg
Systolic 21 2166 16 −0.54 (−2.90 to 1.81) 32 (0 to 60) .44b NA NA NA
Diastolic 20 2073 16 −2.05 (−5.39 to 1.29) 86 (79.7 to 90.3) NA NA NA NA
Cholesterol, mg/dL
Total 14 1523 26 NA NA NA −0.07 (−0.27 to 0.13) 57 (22 to 76.3) .54b
High-density
lipoprotein
11 1444 26 NA NA NA −0.07 (−0.26 to 0.11) 51 (2.4 to 75.4) NA
Low-density
lipoprotein
10 1295 24 NA NA NA 0.05 (−0.15 to 0.24) 39 (0 to 70.9) NA
BMI 19 1734 13 −0.38 (−1.20 to 0.44) 59 (32 to 75.3) .34 NA NA NA
Accelerometer and
fitness tracker
7 529 12 0.35 (−1.63 to 2.33) 72 (39.4 to 87.1) .22b NA NA NA
Pedometer 10 1205 13 −0.74 (−1.54 to 0.06) 50 (0 to 75.8) NA NA NA NA
Weight, kg 17 1758 16 0.13 (−2.70 to 2.96) 52 (16.5 to 72.4) .92 NA NA NA
Accelerometer and
fitness tracker
7 515 18 1.99 (−1.97 to 5.96) 23 (0 to 65.8) .20b NA NA NA
Pedometer 10 1243 16 −1.26 (−5.70 to 3.19) 55 (8.4 to 77.9) NA NA NA NA
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by
height in meters squared); MD, mean difference; MVPA, moderate-vigorous physical
activity; NA, not applicable; SMD, standardized mean difference.
SI conversion factors: To convert cholesterol to millimoles per liter, multiply by 0.0259.
a Hartung-Knapp random-effects meta-analysis was applied for all outcomes.
b P value are for the test for subgroup differences; otherwise the P values are for the test
for heterogeneity in meta-analysis with no subgroups.
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Secondary Outcomes
Interventions with wearable activity trackers were associated with statistically significant reductions
in blood glucose levels compared with comparators (mean difference, −0.14%; 95% CI, −0.27% to
−0.01%) (Table 2). Pedometer-based interventions had the strongest association with improved
blood glucose level (mean difference, −0.19; 95% CI, −0.35 to −0.03); however, accelerometer
performance was not associated with improved blood glucose level in 5 studies.39-43 There were no
associations of wearable activity tracker interventions with systolic blood pressure, diastolic blood
pressure, total cholesterol level, high-density lipoprotein cholesterol level, low-density lipoprotein
cholesterol level, BMI, and weight.
Publication Bias
Publication bias was not obvious for any intervention by visual inspection of the funnel plots
(eFigure 4 in the Supplement) and as indicated by the Egger statistic (test for funnel plot asymmetry:
pedometers: z = 0.97, P = .33; accelerometers: z = 0.49, P = .62). The trim-and-fill method also
confirmed no evidence of publication bias. All forest plots are provided in eFigure 5 in the
Supplement.
Narrative Synthesis
Three pedometer studies37,44,45 and 1 accelerometer study36 reported nonamenable data for meta-
analysis. Two of these studies36,44 reported an association with a greater number of steps, and the
other 2 studies37,45 reported no association with a greater number of steps between intervention and
comparator group.
Discussion
This systematic review and meta-analysis found that interventions using wearable activity trackers
were associated with significant improvements in PA among people with cardiometabolic conditions
compared with individuals who received usual care. Interventions that combined the use of activity
Table 3. Univariable and Multivariable Metaregressions for PA Tracker Use
Covariate of interest b (95% CI) P value I2, % R2, %a
Univariable
Type of tracker: pedometer vs
accelerometer or fitness tracker
0.29 (0.02 to 0.38) .03 51.73 10.57
Outcome measure: steps per day vs MVPA 0.48 (0.04 to 0.76) .04 45.45 15.52
Consultations with facilitators (delivery):
facilitated delivery vs self-reported
0.45 (0.001 to 0.93) .04 35.94 20.44
Index condition: type 2 diabetes vs
overweight or obese or cardiovascular
disease
0.10 (−0.37 to 0.56) .68 43.46 5.27
Sex: male vs female dominant 0.19 (0.03 to 0.29) .02 43.05 0.58
Age: <50 vs ≥50 y −0.20 (−0.84 to 0.44) .52 7.82 0.00
Intervention length: ≤4 vs >4 mo −0.36 (−0.81 to 0.08) .16 37.77 14.60
Goal set for PA: yes vs no −0.11 (−0.62 to 0.40) .66 43.01 0.00
Uptake: ≥80% vs <80% −0.23 (−0.69 to 0.23) .32 41.85 0.00
Use of theoretical concept: yes vs no −0.26 (−0.63 to 0.11) .16 15.82 0.57
Studies with low risk of bias: yes vs nob 0.17 (−0.35 to 0.69) .49 8.21 4.28
Multivariable
Type of tracker 0.20 (0.02 to 0.32) .004 NA NA
Outcome measure −0.01 (−0.10 to 0.03) .06 NA NA
Consultations with facilitators (delivery) −0.04 (−0.11 to −0.01) .01 NA NA
Sex 0.48 (0.01 to 0.96) .046 NA NA
Model fit χ 23 = 24.18 .03 NA NA
Abbreviations: MVPA, moderate-to-vigorous physical
activity; NA, not applicable; PA, physical activity.
a R2 is the estimated proportion of variance in the
dependent variable.
b Low risk of bias was classified as if all risk of bias
domains were judged as low risk.
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trackers with additional components, such as regular consultation sessions with a health care
professional (face to face or remotely), had the strongest associations with PA improvement. The PA
improvements were more pronounced among male participants.
Pedometer use had a significant association with improved PA when used in the context of
interventions that involved regular consultations with a health care professional compared with self-
monitoring interventions without consultations. Accelerometer and fitness tracker interventions
were not associated with PA levels compared with comparators when simple self-monitoring or
Figure 2. Subgroup Meta-analysis of Delivery and Consultation Type by Intervention
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regular consultation-based interventions were used. However, the current comparison involved only
8 studies35,36,41,57,65,69,73,77 compared with 26 pedometer
studies35,38,41,43,45,46,48,49,53,55,57,64-69,71,72,74-81 and few patients, and although the effect size was
larger for accelerometer and fitness tracker interventions (0.92 vs 0.68 for the pedometer), the 95%
CI was wider than that for pedometers. All these factors should be considered when interpreting the
efficacy of the interventions. Pedometers are often criticized because they do not measure daily
steps precisely enough but may be more suited in the short term for patients with high-risk
conditions with an objective of reaching a certain number of steps per day. Moreover, interventions
using pedometers typically measured PA using steps per day, whereas interventions using
accelerometer or fitness trackers measured PA using MVPA. Thus, the choice of PA measurement
(steps per day vs MVPA) might account for the differential performance of these interventions.
Some findings showed that interventions were associated with improved PA levels when they
included consultations and longer periods of PA engagement (ie, longer and more regular sessions).
However, 9 studies38,43,44,48,50,69,70,76,81 did not report the total PA engagement time per session.
Interventions were also associated with reduced blood glucose levels. Although the change was
statistically significant compared with the usual care group, the clinical relevance of the magnitude
of change was small. Other secondary health outcomes, such as blood pressure, cholesterol levels,
weight, and BMI, were not associated with the intervention.
The findings of this review are consistent with the results of earlier systematic reviews17,48 involv-
ing populations at high risk that suggested improvements in PA levels at short-term follow-up assess-
ments when using wearable trackers. One review48 reported an association of a wearable tracker inter-
vention with increased PA level (SMD, 0.57; 95% CI, 0.24-0.91) but was based solely on people with
type 2 diabetes. Furthermore, a recent systematic review and meta-analysis by Brickwood et al23 of
consumer-based wearable activity trackers in general populations indicated an association with im-
proved PA levels, but availability of long-term follow-up data was limited. Although that study was simi-
lar to the present study with regard to the focus on electronic devices for monitoring PA, the population
does not overlap with that in the present study; the study by Brickwood et al23 focused on studies con-
ducted among healthy general populations and not among those at risk for chronic conditions. Another
study18 of wearable devices, mostly including fitness trackers, found that these devices were associated
with improved physical health in clinical populations with cardiometabolic diseases. None of the afore-
mentioned reviews used metaregressions to robustly examine factors associated with the effective-
ness of these interventions. Findings from the current analysis support the use of interventions that
contain consultation sessions with health professionals for boosting the PA benefits for people with
cardiometabolic conditions.
In this study, interventions of the use of wearable activity trackers and in particular pedometers
were associated with greater PA levels per day among people with cardiometabolic conditions.
Nevertheless, the improvements were generally lower than those recommended in the 2018 Physical
Activity Guidelines Advisory Committee Scientific Report by the US Department of Health and Human
Services50 and in other recommendations from global governments and agencies.51 For instance,
the National Obesity Forum UK classified 3000 to 6000 steps per day as sedentary, the Northern
Irelands Public Health Agency promoted an additional 3000 steps, and the America on the Move
program suggested an additional 2000 steps each day to stop weight gain.77 For accelerometers and
fitness trackers, public health guidelines have endorsed 30 minutes (up to 60 minutes) per day (or
150-210 minutes per week) in MVPA, typically in minimal 10-minute bouts.52,53 However, MVPA time
engagement could not be assessed because the total session times were reported inconsistently or
sometimes not at all reported in studies.
The findings of the present study suggest that interventions that combine the use of monitoring
devices (particularly pedometers) with regular consultations with health care professionals
predominantly among male participants are associated with the greatest PA improvements and that
these interventions may help reach the recommendations of governments and agencies for people
with cardiometabolic conditions. Giving feedback and lifestyle advice to patients regularly may
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support the effectiveness of these interventions. A previous study54 suggested positive associations
of multimodal pedometer interventions with PA levels in a variety of populations, including those
with type 2 diabetes and cardiac conditions, but to our knowledge, this was the first study to assess
the association of face-to-face consultations and measurement with PA levels in people with
cardiometabolic conditions. These findings warrant consideration in future trials and further
investigation using more robust methods, such as meta-analyses of individual participant data. The
choice of measurement outcome (steps or MVPA) and their performance differences also need to be
better understood in these patient populations.
Only 1 study55 reported data on the association of a pedometer-based intervention with PA
levels recorded after a 1-year follow-up period. Long-term follow-up assessments are needed to
generate evidence regarding the sustainability of the association over time. Providing longer-term
assessments of these interventions may have greater potential to impact the clinical outcome
performance and might provide more information on the intervention program than current short-
term assessments.
Strengths and Limitations
This study has strengths. First, 4 major databases were searched for relevant literature. Second, the
analysis used well-established statistical methods, including multilevel, multivariable
metaregression, to explore the association of certain moderators with the outcome of interest.
This study also has limitations. Because the included studies did not provide amenable data for
scores, correlations, or SD changes before and after the intervention, the effects of changes at
baseline could not be considered in the meta-analysis, which could have affected the results.
Furthermore, because the PA promotion technique was poorly reported across studies, we were not
able to assess this in regression analysis. Metaregressions were performed to explore the
heterogeneity observed in the main analyses, but important uncertainties remained regarding risk of
bias assessments with many unclear domains, and participant characteristics, such as age and sex,
were based only on aggregate data. In addition, it was not possible to assess for commercial bias
because few studies declared their commercial interests. Because of the heterogeneous nature of
cardiovascular disease index among the 8 trials35,36,41,57,65,69,73,77 and the limited number of trials
that focused on participants with overweight or obesity, the trials were combined under the
definition of a cardiometabolic condition. Only study populations at risk for a cardiometabolic
condition were accepted as part of our inclusion criteria; however, this is a potential limitation
because studies that did not explicitly report this may have been missed. In addition, it was not
possible to look at behavior change outcomes, such as those reported in line with the theoretical
domains framework, because only 1 trial49 mentioned explicitly in their aims that such outcomes
would be collected.
Conclusions
In this systematic review and meta-analysis of individuals with cardiometabolic conditions, interventions
that combined activity trackers (especially pedometers) with complementary intervention components,
such as consultations with health care professionals, were significantly associated with increased levels
of PA. Understanding how to improve these interventions further for greater PA improvements in the
longer term may have implications in the care of people with cardiometabolic conditions.
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